LL-37 Cathelicidin Antimicrobial Peptide – An Alzheimer’s Disease Therapy Candidate
Posted on October 30th, 2018
LL-37 or Human Cathelicidin Antimicrobial Peptide (CAMP) Background
The cathelicidin family of antimicrobial peptides are found in human and mammalian forms of life, as a mammal’s core tool to fight off microbial invasion of all kinds. The genes associated with the peptides have been thoroughly studied, are well-documented and have been compared between species. Other than a prehensile thumb, one of the most interesting unique aspects of humans is we only have one cathelicidin antimicrobial peptide gene: human gene LL-37.
What is Alzheimer’s
Posted on July 3rd, 2018
Alzheimer’s is a complex, systemic disease that slowly erodes a person’s memories, personality, bones and body over a period of 5-10 years. It is difficult or impossible to research and develop a targeted drug to treat the horrid disease due to lack of a single cause. A large body of work shows that Alzheimer’s and other age-related cognitive impairment is related to several causes which are personalized to each patient, including brain inflammation, systemic toxins like heavy metals, lack of sleep, malnutrition, traumatic brain injury, vascular dementia, infections, and literally dozens of others. These various causes impact cognitive performance separately, and have an entourage effect leading to immunosenescence, accelerated aging and death.
Alzheimer’s Disease is the only disease in the top ten causes of death that cannot be cured, prevented or even slowed. Alzheimer’s is a terminal diagnosis which carries with it one of the highest suicide rates. Now is the time to wage war on this epidemic disease the way our elders – the greatest generation – eradicated polio in America. In fact, Alzheimer’s is like a sniper targeting that same greatest generation, our elders.
Our company, MaxWell Biosciences, is submitting an investigational new drug to the FDA – a specialty plasma meant to be mixed as a personalized cocktail for each patient. It has been 14 years since a new drug for Alzheimer’s disease was approved by the FDA.
Biomarkers of Alzheimer’s Disease
Posted on February 24th, 2017
Early detection of Alzheimer’s Disease is paramount to beginning early treatment. Early treatment – prior to high levels of amyloid beta tangles and permanent brain damage has a much higher chance of success.
Type 1 Alzheimer’s – Inflammatory
Posted on February 21st, 2017
Alzheimer’s disease (AD) is not one disease but more of a gradual change in many inputs – a network effect – similar to the downward slide a regional economy might experience during a recession. Alzheimer’s involves progressive neurodegeneration in the presence of misfolded proteins, poorly-understood inflammatory changes. So, Alzheimer’s a uniquely personalized degenerative condition: genetically, clinically, and pathologically heterogeneous (Sudduth et al) [R]. One clear marker of of Alzheimer’s is high levels of inflammation comorbid with cognitive impairment (often referred to as “brain fog” in the young) advancing to intermittent amnesia leading to true dementia.
Lymphatic Fluid and Immunotherapy
Posted on February 15th, 2017
Lymph is the fluid that circulates throughout the lymphatic system. Lymph fluids transport key immune system actors called immunoglobulins and antimicrobial medium and short chain fatty acids (SCFAs) through out the body.
The Biomarkers of Aging – How to Manage Aging
Posted on January 20th, 2017
What is measurable is manageable: tracking and managing the biomarkers of aging means longer health span.
At MaxWell Biosciences, we are aware that the longevity of human aging has dramatically changed throughout the evolution of the species. In order to track these ongoing changes in the rate of aging we must establish pathological biomarkers. Biomarkers of aging are changes in the body that are objectively measurable and show significant differences throughout the chronological stages of human life.